Which FGFR inhibitor do you prefer for patients with cholangiocarcinoma and an FGFR2 gene rearrangement?   

Would you always offer an FGFR inhibitor as second line therapy in these patients instead of a second line chemotherapy regimen?



Answer from: Medical Oncologist at Academic Institution